A Randomized First-in-Human Study With UB-312, a UBITh(R) alpha-Synuclein Peptide Vaccine. Yu HJ, Thijssen E, van Brummelen E, van der Plas JL, et al. Mov Disord 2022;37:1416-1424.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Yu HJ, Thijssen E, van Brummelen E, van der Plas JL, et al. A Randomized First-in-Human Study With UB-312, a UBITh(R) alpha-Synuclein Peptide Vaccine. Mov Disord 2022;37:1416-1424.
PMID: 35426173